Report for: Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care

Title	Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care
Published in	Trials, July 2022
DOI	10.1186/s13063-022-06492-6
Pubmed ID	35804433
Authors	Sarah L. Alderson, Alexandra Wright-Hughes, Alexander C. Ford, Amanda Farrin, Suzanne Hartley, Catherine Fernandez, Christopher Taylor, Pei Loo Ow, Emma Teasdale, Daniel Howdon, Elspeth Guthrie, Robbie Foy, Matthew J. Ridd, Felicity L. Bishop, Delia Muir, Matthew Chaddock, Amy Herbert, Deborah Cooper, Ruth Gibbins, Sonia Newman, Heather Cook, Roberta Longo, Hazel Everitt

X Demographics

The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.

Type	Count	As %
Members of the public	9	60%
Scientists	4	27%
Practitioners (doctors, other healthcare professionals)	2	13%

Mendeley readers

The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Country	Count	As %
Unknown	40	100%

Readers by professional status	Count	As %
Student > Master	4	10%
Unspecified	3	8%
Researcher	3	8%
Student > Bachelor	3	8%
Student > Doctoral Student	2	5%
Other	9	23%
Unknown	16	40%

Readers by discipline	Count	As %
Medicine and Dentistry	6	15%
Unspecified	3	8%
Psychology	3	8%
Social Sciences	3	8%
Business, Management and Accounting	2	5%
Other	7	18%
Unknown	16	40%

Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care